Moomoo AI 已提取核心訊息
On February 27, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made through a press release and included updates on the company's business operations and pipeline progress. Recursion reported a net loss of $93.0 million for the fourth quarter and $328.1 million for the fiscal year. Despite the losses, the company highlighted several key developments, including the progress of multiple clinical programs expected to provide Phase 2 data in the second half of 2024 and the first half of 2025, and the in-licensing of a novel program for treating fibrotic diseases. Recursion also emphasized its integration of causal AI models into its operating system, following a data partnership...Show More
On February 27, 2024, Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The announcement was made through a press release and included updates on the company's business operations and pipeline progress. Recursion reported a net loss of $93.0 million for the fourth quarter and $328.1 million for the fiscal year. Despite the losses, the company highlighted several key developments, including the progress of multiple clinical programs expected to provide Phase 2 data in the second half of 2024 and the first half of 2025, and the in-licensing of a novel program for treating fibrotic diseases. Recursion also emphasized its integration of causal AI models into its operating system, following a data partnership with Tempus. The company's cash and cash equivalents stood at $391.6 million as of December 31, 2023. Additionally, Recursion announced an updated investor presentation and a presentation made in connection with its L(earnings) call, both of which were released on the same day as the financial results. The company uses various channels, including SEC filings, its investor relations website, press releases, public conference calls, webcasts, and social media, to communicate with investors and the public.
2024年2月27日,臨床階段的TechBio公司Recursion Pharmicals, Inc. 公佈了截至2023年12月31日的第四季度和財年的財務業績。該公告是通過新聞稿發佈的,其中包括公司業務運營和管道進展的最新情況。Recursion報告稱,第四季度淨虧損9,300萬美元,本財年淨虧損3.281億美元。儘管出現虧損,但該公司還是強調了幾項關鍵進展,包括預計將在2024年下半年和2025年上半年提供2期數據的多個臨床項目的進展,以及一項治療纖維化疾病的新計劃的許可。在與Tempus建立數據合作關係之後,Recursion還強調將因果人工智能模型集成到其操作系統中。截至2023年1...展開全部
2024年2月27日,臨床階段的TechBio公司Recursion Pharmicals, Inc. 公佈了截至2023年12月31日的第四季度和財年的財務業績。該公告是通過新聞稿發佈的,其中包括公司業務運營和管道進展的最新情況。Recursion報告稱,第四季度淨虧損9,300萬美元,本財年淨虧損3.281億美元。儘管出現虧損,但該公司還是強調了幾項關鍵進展,包括預計將在2024年下半年和2025年上半年提供2期數據的多個臨床項目的進展,以及一項治療纖維化疾病的新計劃的許可。在與Tempus建立數據合作關係之後,Recursion還強調將因果人工智能模型集成到其操作系統中。截至2023年12月31日,該公司的現金及現金等價物爲3.916億美元。此外,Recursion還宣佈了最新的投資者演示文稿和與L(收益)電話會議相關的演示文稿,兩者均與財務業績同日發佈。該公司使用各種渠道與投資者和公衆溝通,包括美國證券交易委員會的文件、其投資者關係網站、新聞稿、公開電話會議、網絡直播和社交媒體。
有用
沒用